Enveric Biosciences, Inc.
ENVB
$1.21
-$0.08-6.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.70M | 5.15M | 6.00M | 7.97M | 8.99M |
| Depreciation & Amortization | 337.50K | 339.70K | 341.20K | 342.90K | 344.00K |
| Other Operating Expenses | -246.10K | -107.20K | -107.20K | -107.20K | -107.20K |
| Total Operating Expenses | 9.63M | 8.84M | 10.21M | 14.07M | 16.45M |
| Operating Income | -9.63M | -8.84M | -10.21M | -14.07M | -16.45M |
| Income Before Tax | -9.57M | -9.83M | -10.56M | -15.04M | -17.26M |
| Income Tax Expenses | 8.90K | 24.00K | 30.60K | 30.60K | 28.90K |
| Earnings from Continuing Operations | -9.57 | -9.86 | -10.59 | -15.07 | -17.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.57M | -9.86M | -10.59M | -15.07M | -17.29M |
| EBIT | -9.63M | -8.84M | -10.21M | -14.07M | -16.45M |
| EBITDA | -9.29M | -8.50M | -9.87M | -13.72M | -16.10M |
| EPS Basic | -21.32 | -39.07 | -55.04 | -96.87 | -122.31 |
| Normalized Basic EPS | -13.31 | -24.33 | -34.28 | -60.23 | -75.57 |
| EPS Diluted | -21.32 | -39.07 | -55.04 | -96.87 | -122.31 |
| Normalized Diluted EPS | -13.31 | -24.33 | -34.28 | -60.23 | -75.57 |
| Average Basic Shares Outstanding | 2.01M | 1.51M | 1.07M | 703.90K | 575.70K |
| Average Diluted Shares Outstanding | 2.01M | 1.51M | 1.07M | 703.90K | 575.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |